Uses of Diverted Methadone and Buprenorphine by Opioid-Addicted Individuals in Baltimore, Maryland

REFERENCES

• Des Jarlais DC, Paone D, Friedman SR, Peyser N, Newman RG. Regulating controversial programs for unpopular people: Methadone maintenance and syringe exchange programs. Am J Public Health. 1995;85:1577–1584.
   PubMed Web of Science ®Google Scholar
• Lewis DC. Access to narcotic addiction treatment and medical care: Prospects for the expansion of methadone maintenance treatment. J Addict Dis. 1999;18:5–21.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Highfield DA, Jaffe JH, A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63:102–109.
   PubMed Web of Science ®Google Scholar
• Cooper JR. Methadone treatment and acquired immunodeficiency syndrome. JAMA. 1989;262:1664–1668.
   PubMed Web of Science ®Google Scholar
• Hser Y-I, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58:503–508.
   PubMed Web of Science ®Google Scholar
• Kinlock TW, Hanlon TE, Nurco DN. Heroin use in the United States: History and present developments. In: Inciardi JA, Harrison L, eds. Heroin in the age of crack-cocaine. Thousand Oaks, CA: Sage; 1998:1–30.
   Google Scholar
• Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267:2750–2755.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of LAAM, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290–1297.
   PubMed Web of Science ®Google Scholar
• Jones HE. Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect. 2004;2:4–19.
   PubMedGoogle Scholar
• Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007;8:171–183.
   PubMed Web of Science ®Google Scholar
• Dupont RL. Heroin addiction treatment and crime reduction. Am J Psychiatry. 1972;128:853–860.
   Google Scholar
• Massing M. The fix. New York, NY: Simon & Schuster; 1998.
   Google Scholar
• Agar M, Reisinger HS. A tale of two policies: The French connection, methadone, and heroin epidemics. Cult Med Psychiatry. 2002;26:371–396.
   PubMed Web of Science ®Google Scholar
• Green MH, Brown BS, DuPont RL. Controlling the abuse of illicit methadone in Washington DC. Arch Gen Psychiatry. 1975;32:221–226.
   PubMedGoogle Scholar
• Rettig RA, Yarmolinksy A, eds. Treatment standards and optimal treatment. In: Federal regulation of methadone treatment. Washington, DC: Institute of Medicine, National Academy Press; 1995:185–216.
   Google Scholar
• Spunt B, Hunt DE, Lipton DS, Goldsmith DS. Methadone diversion: a new look. J Drug Issues. 1986;16:569–583.
   Web of Science ®Google Scholar
• Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict. 2004;13:S17–28.
   PubMed Web of Science ®Google Scholar
• Agar M, Bourgois P, French J, Murdoch O. Buprenorphine: “Field trials” of a new drug. Qual Health Res. 2001;11:69–84.
   PubMed Web of Science ®Google Scholar
• Roux P, Villes V, Blanche J, Buprenorphine in primary care: Risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend. 2008;97:105–113.
   PubMed Web of Science ®Google Scholar
• Parfitt T. Designer drug Subutex takes its toll in Tbilisi. Lancet. 2006;368:273–274.
   PubMed Web of Science ®Google Scholar
• Simojoki K, Vorma H, Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy. 2008;3:16.
   Google Scholar
• Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue. Addiction. 2005;100:197–205.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL. Case series of buprenorphine injectors in Kuala Lumpur, Malaysia. Am J Drug Alcohol Abuse. 2008;34:511–517.
   PubMed Web of Science ®Google Scholar
• Chowdhury AN, Chowdhury S. Buprenorphine abuse: report from India. Br J Addiction. 1990:85:1349–1350.
   PubMedGoogle Scholar
• Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 2003;69:175–181.
   PubMed Web of Science ®Google Scholar
• U.S. Dept of Health and Human Services. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: A treatment improvement protocol. Rockville, MD: Department of Health and Human Services, Publication No. (SMA) 04-3939; 2004.
   Google Scholar
• Fountain J, Strang J, Gossop, Farrel M, Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction. 2000;95:393–406.
   PubMed Web of Science ®Google Scholar
• Davis WR, Johnson BD. Prescription opioid use, misuse and diversion among street drug users in New York City. Drug Alcohol Depend. 2008;92:267–276.
   PubMed Web of Science ®Google Scholar
• Vlahov D, O'Driscoll P, Mehta SH, Risk factors for methadone outside treatment programs: implications for HIV treatment among injection drug users. Addiction. 2007;102:771–777.
   PubMed Web of Science ®Google Scholar
• Hunt DE, Lipton DS, Goldsmith DS, Strug DL, Spunt B. “It takes your heart”: The image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int J Addict. 1986;20:1751–1771.
   Google Scholar
• Schwartz RP, Kelly SM, O'Grady KE, In-treatment v. out-of-treatment opioid dependent adults: drug use and criminal history. Am J Drug Alcohol Abuse. 2008;34:17–28.
   PubMed Web of Science ®Google Scholar
• Peterson JP, Reisinger HS, Schwartz RP, Targeted sampling in drug abuse research: A review and case study. Field Methods. 2008;20:155–170.
   Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, O'Grady KE, Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008;17:396–401.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Alterman AL, Woody GE, Metzger D. A quantitative measure of substance abuse treatments: the Treatment Services Review. J Nerv Ment Dis. 1992;180:101–110.
   PubMed Web of Science ®Google Scholar
• Nurco DN, Hanlon TE, Bateman RW, Toledano E, Kinlock TW. Policy implications derived from an experimental intervention involving drug-abusing offenders. The Prison Journal. 1993;73:332–342.
   Google Scholar
• Kosten TR, Rounsaville BJ, Kleber HD. Concurrent validity of the Addiction Severity Index. J Nerv Ment Dis. 1983;171:606–610.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Cacciola JS, New data from the ASI: Reliability and validity in three centers. J Nerv Ment Dis. 1985;173:412–423.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. J Nerv Ment Dis. 1980;168:26–33.
   PubMed Web of Science ®Google Scholar
• Strauss A, Corbin J. Basics of qualitative research grounded theory procedures and techniques. Newbury Park, CA: Sage; 1991.
   Google Scholar
• U.S. Drug Enforcement Administration. DEA Fact Sheet. July 11, 2008.
   Google Scholar
• Wu LT, Blazer DG, Stitzer ML, Patkar AA, Blaine JD. Infrequent illicit methadone use among stimulant-using patients in methadone maintenance treatment programs: a national drug abuse treatment clinical trials network study. Am J Addict. 2008;17:304–311.
   PubMed Web of Science ®Google Scholar
• Roche A, McCabe S, Smythe BP. Illicit methadone use and abuse in young people accessing treatment for opiate dependence. Eur Addict Res. 2008;14:219–225.
   PubMed Web of Science ®Google Scholar
• Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment: a review of historical and clinical issues. Mt Sinai J Med. 2000;67:347–364.
   PubMed Web of Science ®Google Scholar
• Newman RG. Methadone treatment in narcotic addiction: Program management, findings, and prospects for the future. New York, NY: Academic Press; 1977.
   Google Scholar
• Reisinger HS, Schwartz RP, Mitchell SG, . Premature discharge from methadone treatment: patient perspectives. J Psychoactive Drugs in press.
   Web of Science ®Google Scholar
• Buning EC, van Brussel GHA, van Santen G. The “methadone by bus” project in Amsterdam. Br J Addict. 1990;85:1247–1250.
   PubMedGoogle Scholar
• Schwartz RP, Highfield DA, Jaffe JH, Callaman JM, O'Grady KE. A randomized controlled trial of interim methadone maintenance: 10 month-follow-up. Drug Alcohol Depend. 2007;86:30–36.
   PubMed Web of Science ®Google Scholar
• Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003–2005. J Addict Dis. 2007;26:107–111.
   PubMed Web of Science ®Google Scholar
• Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003 21;70( 2 Suppl):S3–11.
   Google Scholar
• Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Pub Health. 2009;99:221–227.
   PubMed Web of Science ®Google Scholar
• Darke S, Topp L, Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996–2000: 5-year monitoring of trends from the Illicit Drug Reporting System. Drug Alcohol Rev. 2001;21:27–32.
   Google Scholar
• Graham NA, Merlo LJ, Goldberger BA, Gold MS. Methadone- and heroin-related deaths in Florida. J Drug Alcohol Abuse. 2008;34:347–353.
   PubMed Web of Science ®Google Scholar
• Humeniuk R, Ali R, McGregor C, Darke S. Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction. 2003;98:413–418.
   PubMed Web of Science ®Google Scholar
• NDIC. Methadone diversion, abuse, and misuse: deaths increasing at alarming rate. Publication date: November 16, 2007; document ID: 2007-Q0317-001. Accessed Oct 14, 2008. http://www.justice.giv/mdic/pubs25/25930/index.htm.
   Google Scholar
• Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine-naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther. 2002;303:695–703.
   PubMed Web of Science ®Google Scholar